Patent intelligence · US
US 12076371
Activatable cytokine polypeptides and methods of use thereof
Activatable cytokine polypeptides and methods of use thereof
Patent details — US 12076371
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 3, 2024
- Expiration
- Aug 29, 2044
- Applicant
- Werewolf Therapeutics, Inc.
- Claims
- 29
- CPC classes
- A61K, A61K2239/31, A61K2239/38, A61K2239/48
Quick answer
US 12076371 (Activatable cytokine polypeptides and methods of use thereof) is held by Werewolf Therapeutics, Inc.. Status: granted. Granted Sep 3, 2024. Expires Aug 29, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Werewolf Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 29
- CPC classes
- A61K, A61K2239/31, A61K2239/38, A61K2239/48, A61K35/17, A61K38/00
More from Werewolf Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12275769
Activatable interleukin 12 polypeptides and methods of use thereof
granted -
US 12036266
Activatable cytokine polypeptides and methods of use thereof
granted -
US 11981716
Activatable interleukin-2 polypeptides and methods of use thereof
granted -
US 11739132
Separation moieties and methods of use thereof
granted -
US 11535658
Activatable interleukin-2 polypeptides and methods of use thereof
granted -
US 11453710
Activatable interleukin 12 polypeptides and methods of use thereof
granted -
US 11352403
Activatable interleukin-2 polypeptides and methods of use thereof
granted
Frequently asked questions
What is US patent 12076371?
US 12076371 (Activatable cytokine polypeptides and methods of use thereof) is held by Werewolf Therapeutics, Inc.. Status: granted. Granted Sep 3, 2024. Expires Aug 29, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12076371?
Werewolf Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 10 pharmaceutical patents for this assignee.
When does US 12076371 expire?
Our index shows an expiration date of Aug 29, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.